Beneficios de los compuestos bioactivos del mangostán en la enfermedad de Alzheimer: Revisión narrativa
I Navarro-González, P Andreo-Martínez… - 2021 - rua.ua.es
La enfermedad de Alzheimer (EA) es una enfermedad neurodegenerativa irreversible,
acompañada de pérdida de memoria y de déficit neurocognitivo progresivo. Los cambios …
acompañada de pérdida de memoria y de déficit neurocognitivo progresivo. Los cambios …
[PDF][PDF] Intracellular Library Screening to Derive Novel Peptide-based Inhibitors of Toxicity in Alzheimer's Disease
R Carver - 2022 - researchportal.bath.ac.uk
Alzheimer's Disease (AD) is the most common form of dementia with around 520,000
individuals currently diagnosed in the UK. The misfolding and aggregation of the peptide …
individuals currently diagnosed in the UK. The misfolding and aggregation of the peptide …
Antisense oligonucleotide-mediated exon skipping strategies as the treatment for rare diseases
D Li - 2020 - researchportal.murdoch.edu.au
Antisense oligomer-mediated exon skipping is being developed as a strategy for
personalised treatment of genetic disorders through excising “in-frame” exons carrying small …
personalised treatment of genetic disorders through excising “in-frame” exons carrying small …
Splice-switching Antisense Oligonucleotides as a Therapeutic for Alzheimer's Disease
JL Chang - 2018 - search.proquest.com
Abstract Alzheimer's disease (AD), a devastating neurodegenerative disease, is the most
common cause of dementia worldwide, which currently has no cure. Therapies have thus far …
common cause of dementia worldwide, which currently has no cure. Therapies have thus far …